{"name":"BioLineRx, Ltd.","slug":"biolinerx-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"BL 1020 High Dose","genericName":"BL 1020 High Dose","slug":"bl-1020-high-dose","indication":"Schizophrenia","status":"phase_2"},{"name":"BL-7040","genericName":"BL-7040","slug":"bl-7040","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BL - 1020","genericName":"BL - 1020","slug":"bl-1020","indication":"Diabetic nephropathy","status":"phase_2"}]}],"pipeline":[{"name":"BL - 1020","genericName":"BL - 1020","slug":"bl-1020","phase":"phase_2","mechanism":"BL-1020 is a vasopressin V2 receptor antagonist.","indications":["Diabetic nephropathy"],"catalyst":""},{"name":"BL 1020 High Dose","genericName":"BL 1020 High Dose","slug":"bl-1020-high-dose","phase":"phase_2","mechanism":"BL 1020 is a dopamine D3 receptor antagonist that modulates dopaminergic signaling in the brain.","indications":["Schizophrenia","Bipolar disorder"],"catalyst":""},{"name":"BL-7040","genericName":"BL-7040","slug":"bl-7040","phase":"phase_2","mechanism":"BL-7040 is a small molecule that acts as a sphingosine-1-phosphate receptor 1 (S1P1) modulator.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPVkxNdDJJWHdEbjRZeTJyYmU1blJDR2NMcWQySGRXbzd3dXhybWZJT3pRcUtGOU0zMmFadG9zY0NHS21ZT0dJUTZ5WEowa1VjMlhhZmdOT0N5TXhKS0M0cndvcUtOUTY2eG5wc1Z1SVFQVUI4Z3Q0RVpZMGV1VXpkelVhS0h4dlJXd24wZlRZZk1DV1UyRi1DWGd2SXNOUTN3UVZ1OUtlS3FaUkdRLUhWTDNkOGJOUWxxbjM0Zw?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"BioLineRx (NASDAQ: BLRX) files Form 20-F/A to correct auditor consent - Stock Titan","headline":"BioLineRx (NASDAQ: BLRX) files Form 20-F/A to correct auditor consent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNTUp4c1hRd1lKWGIzcDRMd3V0cmtTWjJyRWMtOXc5c0s4aVhjcU1EVmRGTHhvdWNEdlh6Nl8yVmdIMmFGNGVOMVlvMjR4dm1jX25uQ191X3ZkVi10Q25RU1JESENJU2tUYnlqS003NUw3YUl5bFRnS2VuY2hDaURhZzVxeDE2dTBsX2tiS3pFd1R2c1NuaDFBNDNhcC15aTZJdVZXVlpWaUVKejZfVm1Ia2R0QTU1dw?oc=5","date":"2026-03-23","type":"pipeline","source":"prnewswire.com","summary":"BioLineRx to Report 2025 Annual Results on March 23, 2026 - prnewswire.com","headline":"BioLineRx to Report 2025 Annual Results on March 23, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxNSllBMTZHVHZaaXBIVFpNMmdua3pyN3lvRW5heklxVDRQX3NZWGdxYW9tNlMxQ0dFMTNhaVBrS1BNaEkwSnBwNjh3OVZ3YXJNbEJ3TnQzSnkyd1N6aGlwVm5EMFItTVNIMDBqa3pYQ3YzMlcySEg4Q1NIcTFCTnlxTW00TXlRbGNhVm1XXzZ3ZGktX0ZJcWd0eFNfYXZIZFA5Mk1BVERFNGdNQ1VLbkNONkxrS0RTbUp2YmFkOFdyMXVnZTNGd3FqT0VfU3IxN2tQeTVoMTl3c3dzZ3FZYVQ2WU0tdk4zYm9sV2xrZ2hjQTU1dWtCTkQtekM4QUNIYVdGbzdBSF9LUWx1RFhxa19JZHh2TnN5eE50dDMzUUlkd2lDaDhZU3pXOW5pQUtoampZSURuOXNjQ1dNd0NlSXZyR2NQaUNFTEZkck9RS1Z4YTU?oc=5","date":"2025-09-29","type":"pipeline","source":"prnewswire.com","summary":"BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - prnewswire.com","headline":"BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQVWZmYk9tTmZCQTRad0JJekl2ZExJN0M4TFFPTVhhLW5ObzdCMjl2M2gtU2hwWUNjSkNKNzFPNnRremJTQmNiNjFXZHFzcjB2cWZWV2NHTmlvZUhBT1FDeUhGdG1FRFV1QTM4RkQxVDcxQ1Vqd1hFa1VubFFMNlQ4T3dYNV9RVXJIcFM0LXdIN29FclVIeXlaTHdveGx6SWltZU5STnMxSHBmM2FLYUdOSGtDelVNRmNpcmtpd1dadFV3c0xK?oc=5","date":"2025-04-13","type":"pipeline","source":"The Times","summary":"Wiley Joe gets cash injection for struggling stem cell start-up - The Times","headline":"Wiley Joe gets cash injection for struggling stem cell start-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNN2ZtU2ZjaDFnUkVSM21JTURuM2NtdTUzcGtZdE5wVkNqN1JHYzhiZjFDMk12SFZoTnUwbW1sNDFKWXBKMnBONEpNZmZOQzA0OFprMkZWRWVtaVNhZkJaOGtRNV9QUVUwRDYzemxkNDlaTFZKME9EVUZDUHFHaDlIdGdsRHdRMkF3MVhqa3FJMXZFdnlFUVJ1ZHhySjNMaFF5QjloZWVUM0lsMlpEVktwVlA1ZF8wdVRUaDZXcTF0WW0xNERnNENtMmpkaHhmQ3M2ZEVuSFR6eWNBaFRMVWpYbGZ4V2FDRjVjSElqTmZyMnNGa3JBQkJWQXNWZ1Z4STQ5ejNyaUk4LXVUWl9VRTRJ?oc=5","date":"2024-11-21","type":"deal","source":"prnewswire.com","summary":"BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - prnewswire.com","headline":"BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9WeF9zTzlxUjJxend0Wm51YVk0RDc1RFhVTUJEX1IwLUtTT1BZX3F2RWk3SV9FTGxSVktKME1YM0hIUXBwMXJ4TTVaNFVDV1lI?oc=5","date":"2024-03-15","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBrVnMtMnd5dGx5bldlT2F0TDcxZlpSWDkwTW0tQm9KQ1BISlo1dGhIM1NGWUE4alFydmp4a1ktM1NPOHlJbTFDcUV1X05yS1c5ZlhOV2dLODQyR2ZnZkJoLWtCMkNrTDJOeFlmbEJES1ZqbWt5TVNqU2VEcw?oc=5","date":"2020-12-03","type":"regulatory","source":"acsjournals.onlinelibrary.wiley.com","summary":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and eff","headline":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE0wMDZJcnJMSktaWG91MkVQT0kzV1VOYmU2YlJ5UnMzV3Y0TkU5UUc1THVqWFAtMXR3aF9ZanhISG1td2lhZ0lRakY5Tlpqa3JlbEhTVEFXMXJVRkhDa2pGUHhLTDhqS0E?oc=5","date":"2018-07-31","type":"deal","source":"proactiveinvestors.com","summary":"BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim - proactiveinvestors.com","headline":"BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBpYW9UTkdIZDFyREZBUXFpX3NCZVc1WnhMM3J0TFZqbHZMX1daSXBVUTZJU1lWZTViLTRKcHctRjc0cUFoTzA5TGpCbmRGV2p0SEFZV280SEVIRXhGSDBHYmk0WXBHenpPTDFqaFl2VGxFZjBGSDFyMm81N3ZUQ2s?oc=5","date":"2018-02-06","type":"trial","source":"Yahoo Finance","summary":"Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040 - Yahoo Finance","headline":"Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9lQ3VDSTdtYjlGdVlRUHBZTkJkWGxrSW0wSXdNVlFPSHM2bUZuQTB3R0MxR1IwZHpDd2JRME0zSjEycW9ibzN4LWhJbVI1S2dpeUQ1VTUtNUduZw?oc=5","date":"2017-11-02","type":"pipeline","source":"TradingView","summary":"BLRX Stock Price and Chart — TASE:BLRX - TradingView","headline":"BLRX Stock Price and Chart — TASE:BLRX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNTnVqSXNTM01Bc0U2SUFHanJkZGlDYW10YV8xS19nVURtYmlMVVJTb0llTXJBTmdlVjBRT1FJY1liYTFDSkZ3VjBadXlwcnFVOWtzalZSYUFMOWZRVE9PVG9JMGVwXzdEcDdrM2I2ZEh2SWNFWnB1Ml92SFRlaXZsM2JtQWlkVU9sZXNwcTJR?oc=5","date":"2015-02-15","type":"pipeline","source":"Globes - Israel Business News","summary":"Novartis seeks new Israeli technologies - Globes - Israel Business News","headline":"Novartis seeks new Israeli technologies - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPd0VfcnZBMFNsOWdia2Nxem1HNXUtakxyNExaUkxZTFQ1Q3F5WERib1RteEdmMHRQQmlHbDRxREVRbkxZeGdxRk9RckVRa1RkSkdQVE01LW1tQTRINW9KZmt1eVkxSWRWX0lwSEpXMG1VdUdvTXRpcEhPd3lrUFRPU09qZW40aVhqUEpaclozRWVFWXFqNUVXTHg1cDN2YnJ1cjd1azB5d2RvZUI2OV9odlF6SV95bG9VQXBURWRJMG05UEY2OU5OcXVoRzh3SUhROVkyQURwWnhCNWZWZF9tZmM1ZTllbDBIRXpOTzVPNEhEQVY1WHc?oc=5","date":"2007-05-19","type":"pipeline","source":"RTTNews","summary":"Pharma Sector: Few Newsmakers Of The Week - Pharmaxis, Celgene, Opexa, Genzyme, BioLineRx, Medarex, Boehringer, Acambis, Wyeth, Imclone - RTTNews","headline":"Pharma Sector: Few Newsmakers Of The Week - Pharmaxis, Celgene, Opexa, Genzyme, BioLineRx, Medarex, Boehringer, Acambis,","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}